ASCO 2018: Dr. Walter M. Stadler gives his top picks in prostate cancer research

The theme of this year’s annual meeting of the American Society of Clinical Oncology is Delivering Discoveries: Expanding the Reach of Precision Medicine. Of the more than 2,500 abstracts accepted for presentation, Walter M. Stadler, MD, picks the upcoming ASCO presentations he anticipates to be the most interesting in prostate cancer research.

• 5000, A randomized, phase 3 trial between adjuvant docetaxel and surveillance after radical radiotherapy for intermediate and high-risk prostate cancer: Results of SPCG-13 trial.

^{alexdans/Thinkstock}

• 5002, A randomized study of finite abiraterone acetate (AA) plus leuprolide (LHRHa) versus LHRHa in biochemically recurrent nonmetastatic hormone-naïve prostate cancer (M0HNPC).

• 5004, The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E).

• LBA5005, Overall survival between African American (AA) and Caucasian (C) men with metastatic castration-resistant prostate cancer (mCRPC).

• 5006, Results of PROSPECT: A randomized, phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.